These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33672395)
21. An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients. Jareoncharsri P; Bunnag C; Tunsuriyawong P; Assanasane P; Voraprayoon S; Pinkaew B Asian Pac J Allergy Immunol; 2003 Dec; 21(4):223-30. PubMed ID: 15198340 [TBL] [Abstract][Full Text] [Related]
22. Impact of Polyvalent Mechanical Bacterial Lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial. Bartkowiak-Emeryk M; Emeryk A; Roliński J; Wawryk-Gawda E; Markut-Miotła E Allergy Asthma Clin Immunol; 2021 Jan; 17(1):10. PubMed ID: 33472687 [TBL] [Abstract][Full Text] [Related]
23. Dosage Forms Suitability in Pediatrics: Acceptability of Antibiotics in a German Hospital. Klingmann V; Vallet T; Münch J; Wolters L; Stegemann R; Bosse HM; Ruiz F Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136743 [TBL] [Abstract][Full Text] [Related]
24. Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration. Hua S Front Pharmacol; 2019; 10():1328. PubMed ID: 31827435 [TBL] [Abstract][Full Text] [Related]
25. The Importance of Tablet Formulation on Allergen Release Kinetics and Efficiency: Comparison of Freeze-dried and Compressed Grass Pollen Sublingual Allergy Immunotherapy Tablet Formulations. Lund K; Kito H; Skydtsgaard MB; Nakazawa H; Ohashi-Doi K; Lawton S Clin Ther; 2019 Apr; 41(4):742-753. PubMed ID: 30885398 [TBL] [Abstract][Full Text] [Related]
26. [Oral formulation of choice for children]. Lajoinie A; Henin E; Kassai B Arch Pediatr; 2015 Aug; 22(8):877-85. PubMed ID: 26141805 [TBL] [Abstract][Full Text] [Related]
27. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Braido F; Melioli G; Cazzola M; Fabbri L; Blasi F; Moretta L; Canonica GW; Pulm Pharmacol Ther; 2015 Aug; 33():75-80. PubMed ID: 25951945 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010 [TBL] [Abstract][Full Text] [Related]
29. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study. Venables R; Batchelor H; Stirling H; Marriott J Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666 [TBL] [Abstract][Full Text] [Related]
30. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. Rutishauser M; Pitzke P; Grevers G; van Aubel A; Elsasser U; Kämmereit A Adv Ther; 1998; 15(6):330-41. PubMed ID: 10351117 [TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582 [TBL] [Abstract][Full Text] [Related]
32. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372 [TBL] [Abstract][Full Text] [Related]
33. A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population. Wargenau M; Reidemeister S; Klingmann I; Klingmann V Ther Innov Regul Sci; 2022 Nov; 56(6):903-909. PubMed ID: 35471561 [TBL] [Abstract][Full Text] [Related]
34. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Lanzilli G; Falchetti R; Cottarelli A; Macchi A; Ungheri D; Fuggetta MP Int J Immunopathol Pharmacol; 2006; 19(3):551-9. PubMed ID: 17026840 [TBL] [Abstract][Full Text] [Related]
35. Evidence of acceptability of oral paediatric medicines: a review. Mistry P; Batchelor H; J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471 [TBL] [Abstract][Full Text] [Related]
36. [Efficacy and safety of sublingual immunotherapy of allergic rhinitis in children between 4 and 5 years age group and 11 and 12 years age group]. Cui L; Wang ZN; Xu ZQ; Xia ZF Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Jan; 48(1):17-21. PubMed ID: 23656810 [TBL] [Abstract][Full Text] [Related]
37. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial. Tricarico D; Varricchio A; D'Ambrosio S; Ascione E; Motta G Arzneimittelforschung; 2004; 54(1):57-63. PubMed ID: 14979610 [TBL] [Abstract][Full Text] [Related]
38. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Venables R; Batchelor H; Hodson J; Stirling H; Marriott J Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436 [TBL] [Abstract][Full Text] [Related]
39. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539 [TBL] [Abstract][Full Text] [Related]
40. Development and content validation of the Pediatric Oral Medicines Acceptability Questionnaires (P-OMAQ): patient-reported and caregiver-reported outcome measures. Turner-Bowker DM; An Haack K; Krohe M; Yaworsky A; Vivas N; Kelly M; Chatterjee G; Chaston E; Mann E; Reaney M J Patient Rep Outcomes; 2020 Oct; 4(1):80. PubMed ID: 33000327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]